Skip to content

Study · Animal study (in vivo) · mouse · 2013

6 results

Physiological relevance of LL-37 induced bladder inflammation and mast cells.

Oottamasathien S, Jia W, Roundy LM, Zhang J, Wang L, Ye X, Hill AC, Savage J, Lee WY, Hannon AM, Milner S, Prestwich GD

The Journal of urology9 Jan 2013Cited by 12 (Europe PMC)

PMID23313203 (opens in a new tab)PMCIDPMC3947931 (opens in a new tab)DOI10.1016/j.juro.2013.01.002 (opens in a new tab)PepBankPUB-23313203
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In C57Bl/6 mice, intravesical LL‑37 caused more bladder inflammation at higher concentrations.

    In plain wordsIn mice, LL‑37 placed in the bladder caused more bladder inflammation at higher doses.

    Peptide
    LL-37
    Outcome
    IncreaseBladder inflammation across LL-37 concentrations
    Study

    mousen: not reported in source

    C57Bl/6 mice
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    Dose not stated · intravesicalAs given in this study (mouse).

    Source sentences

    Summary
    Mouse LL-37 dose escalation experiments revealed increased inflammation at higher LL-37 concentrations.
    1 context sentence
    Summary · context
    Our second hypothesis was tested in C57Bl/6 mice challenged with 7 LL-37 concentrations intravesically for 1 hour. At 24 hours tissues were examined histologically and myeloperoxidase assay was done to quantitate inflammation.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, fluorescent LL‑37 showed global binding to the urothelium immediately after instillation.

    In plain wordsIn mice, LL‑37 placed in the bladder bound across the whole bladder lining right away.

    Peptide
    LL-37
    Outcome
    IncreaseUrothelial binding of fluorescent LL-37 at time 0
    Study

    mousen: not reported in source

    C57Bl/6 mice
    Outcome group
    Receptor activity and mechanism · Kidney and urinary
    Studied dose
    Dose not stated · intravesicalAs given in this study (mouse).

    Source sentences

    Summary
    Fluorescent LL-37 demonstrated global urothelial binding at time = 0
    1 context sentence
    Summary · context
    In separate experiments fluorescent LL-37 was instilled and tissues were obtained immediately (time = 0) and at 24 hours (time = 24).
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, fluorescent LL‑37 was no longer visible in the urothelium at 24 hours.

    In plain wordsIn mice, LL‑37 placed in the bladder could no longer be seen in the bladder lining after 24 hours.

    Peptide
    LL-37
    Outcome
    DecreaseFluorescent LL-37 signal at 24 hours
    Study

    mousen: not reported in source

    C57Bl/6 mice
    Outcome group
    Receptor activity and mechanism · Kidney and urinary
    Studied dose
    Dose not stated · intravesicalAs given in this study (mouse).

    Source sentences

    Summary
    but was not visible at time = 24.
    1 context sentence
    Summary · context
    In separate experiments fluorescent LL-37 was instilled and tissues were obtained immediately (time = 0) and at 24 hours (time = 24).
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice, intravesical LL‑37 was followed by mast cell infiltration in all bladder tissue layers.

    In plain wordsIn mice, LL‑37 placed in the bladder was followed by mast cells moving into all layers of the bladder wall.

    Peptide
    LL-37
    Outcome
    IncreaseMast cell infiltration in bladder tissue
    Study

    mousen: not reported in source

    C57Bl/6 mice
    Outcome group
    Immune response · Kidney and urinary
    Studied dose
    Dose not stated · intravesicalAs given in this study (mouse).

    Source sentences

    Summary
    Immunohistochemistry for tryptase revealed mast cell infiltration in all tissue layers.
    1 context sentence
    Summary · context
    To test our final hypothesis, we performed immunohistochemistry for mast cell tryptase and evaluated 5 high power fields per bladder to determine the mean number of mast cells per mm(2).
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice, higher LL‑37 concentrations led to significantly greater mast cell infiltration in the bladder.

    In plain wordsIn mice, higher LL‑37 doses in the bladder led to more mast cells moving into the bladder wall.

    Peptide
    LL-37
    Outcome
    IncreaseMast cell infiltration at higher LL-37 concentrations
    Study

    mousen: not reported in source

    C57Bl/6 mice
    Outcome group
    Immune response · Kidney and urinary
    Studied dose
    Dose not stated · intravesicalAs given in this study (mouse).

    Source sentences

    Summary
    At higher concentrations the LL-37 challenge led to significantly greater mast cell infiltration.
    1 context sentence
    Summary · context
    To test our final hypothesis, we performed immunohistochemistry for mast cell tryptase and evaluated 5 high power fields per bladder to determine the mean number of mast cells per mm(2).

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 06HumanEndogenous levelObservational studyOther

    In pediatric patients with spina bifida, urinary LL‑37 was 89-fold higher than in normal patients.

    In plain wordsChildren with spina bifida had much higher levels of the body's own LL‑37 in urine than children without it.

    Peptide
    LL-37
    Outcome
    IncreaseUrinary LL-37 in spina bifida
    Study

    n = 78

    Comparator
    Normal patients
    Outcome group
    Inflammation markers · Kidney and urinary

    Measurements

    fold difference
    89 fold
    spina bifida vs normal patients

    Source sentences

    Summary
    Urinary LL-37 was 89-fold higher in patients with spina bifida.
    1 context sentence
    Summary · context
    To test our first hypothesis, we obtained urine samples from 56 pediatric patients with spina bifida and 22 normal patients. LL-37 was measured by enzyme-linked immunosorbent assay.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:58 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.